Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Amphastar Pharmaceuticals IncTrade
Advanced Drainage Systems IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Advanced Drainage Systems Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.68B). The key difference: Advanced Drainage Systems Inc is far larger — about 12.4× Amphastar Pharmaceuticals Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMPHWMS
Market Cap
$863.95M$10.68B
Sector
HealthIndustrials
52-Week High
$30.81$175.38
52-Week Low
$16.87$129.50
Enterprise Value
$1.26B$12.29B
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Advanced Drainage Systems Inc

Advanced Drainage Systems (WMS) trades at $143.95, down 3.03% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news highlights Q1 fiscal 2027 sales growth of 21% and consistent dividend payments, though cash flow turned negative in 2025 due to increased investing activity.

The outlook is mixed; analyst consensus is a Buy with a $185.86 price target, but near-term risks include volatile cash flows and high valuation multiples. Upside potential hinges on execution of growth initiatives and infrastructure demand, while margin pressure and economic sensitivity pose challenges.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Advanced Drainage Systems Inc

Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe

Read more on WMS